All-cause mortality after five years is much more likely if a TAVR patient presents with CAD, according to a new analysis published in JACC: Cardiovascular Interventions.

After finding success in Europe, the company is focused on gaining FDA approval for its Trilogy Heart Valve System and launching the device in the United States. 

The standard-of-care thinking on TAVR has shifted from getting a valve implanted and managing immediate complications to looking decades down the road and considering the patient's long-term health. 

A care team with the Sanger Heart & Vascular Institute has shared details about its recent successes in TMVR and TAVR. Cardiologist Michael Rinaldi, MD, highlighted the importance of having "a coordinated team of specialists with expertise in treating valve diseases."

The all-day summit, a collaboration between CRF and Fogarty Innovation, will focus on advances in healthcare technologies and patient care.

The news comes after the Onyx Frontier DES gained CE mark approval. It received FDA approval in May.

Overall, PCI patients appear to face a higher risk of in-hospital mortality, 30-day mortality and in-hospital cardiovascular mortality if they present with an active or historical cancer diagnosis. The group's analysis included data from nearly 6.6 million patients.

Philippe Genereux, MD, medical director of the structural heart disease program at Morristown Medical Center, discusses the various options used for temporary pacing of the heart during transcatheter aortic valve replacement (TAVR) procedures.